Related Experiment Videos
Synergistic interaction between topotecan and microtubule-interfering agents
H R Bahadori1, M R Green, C V Catapano
1Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston 29425, USA.
Purpose:
Topotecan is a topoisomerase I inhibitor with demonstrated anticancer activity in preclinical and clinical studies. The purpose of the present study was to evaluate drug-drug interactions in therapeutic regimens that would combine topotecan with microtubule-interfering agents, such as Taxol and vinblastine.
Methods:
The cytotoxic activities of various drug combinations and schedules of administration were measured in a colon cancer cell line using the MTT assay. Western blot and flow cytometry were performed to determine the effects of Taxol and vinblastine on topoisomerase I and Bcl-xL protein levels and cell cycle distribution.
Results:
Brief incubation of colon cancer cells with low concentrations of either Taxol or vinblastine increased the efficacy of a subsequent treatment with topotecan. Preincubation of cells with vinblastine or Taxol reduced by 10- to 40-fold the concentration of topotecan necessary to induce a 50% decrease in cell survival. The effects were maximal when the cells were treated for 5 h with microtubule-interfering agents and then incubated for 19 h in drug-free medium before the addition of topotecan. Under these conditions, both Taxol and vinblastine caused an increase in topoisomerase I protein levels, fraction of S phase cells, and extent of Bcl-xL phosphorylation immediately prior to the addition of topotecan. All these factors may contribute to the increased efficacy of topotecan observed with sequential therapy.
Conclusion:
Combinations of topotecan and microtubule-interfering agents result in synergistic anticancer activity when the drugs are administered sequentially. The promising preclinical data presented here encourage clinical testing of these drug combinations using a sequential schedule of administration.
Insights
Sequential administration of topotecan with microtubule-interfering agents like Taxol and vinblastine enhances anticancer efficacy. This combination shows synergistic activity, supporting further clinical investigation.
Area of Science:
- Pharmacology
- Oncology
- Cell Biology
Background:
- Topotecan is a topoisomerase I inhibitor with known anticancer properties.
- Microtubule-interfering agents such as Taxol and vinblastine are used in cancer therapy.
Purpose of the Study:
- To investigate potential drug-drug interactions between topotecan and microtubule-interfering agents.
- To evaluate the efficacy of combined topotecan and microtubule-interfering agent regimens.
Main Methods:
- Cytotoxic activity of drug combinations assessed using the MTT assay in a colon cancer cell line.
- Western blot and flow cytometry used to analyze protein levels (topoisomerase I, Bcl-xL) and cell cycle distribution.
Main Results:
- Sequential treatment with low-dose Taxol or vinblastine significantly enhanced topotecan's efficacy, reducing required topotecan concentration by 10-40 fold.
- Optimal enhancement occurred after 5-hour incubation with microtubule agents followed by 19 hours drug-free.
- Taxol and vinblastine increased topoisomerase I levels, S-phase fraction, and Bcl-xL phosphorylation prior to topotecan addition.
Conclusions:
- Sequential administration of topotecan with microtubule-interfering agents yields synergistic anticancer activity.
- Preclinical findings support clinical trials of these sequential drug combinations.